Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak
FFF Enterprises and BioNews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of critical-care biopharmaceuticals, plasma products and vaccines, FFF has been pro-active in communicating with pharmaceutical manufacturers across the country, ensuring that patients do not experience interruptions in receiving the lifesaving medicines they need. Through their discussions with patient advocates and industry leaders alike, FFF has identified newly emerging needs for serving rare and orphan disease patient communities during this unprecedented time in history, when isolation and a limitation in treatment options can be difficult. "Many of the patients we serve have spent years ‘self-quarantining’ themselves during flu season or when they felt their immune systems were comprised," states Patrick M. Schmidt, CEO of FFF Enterprises." What they haven't experienced before is the social isolation that comes from a pandemic like COVID-19, and many are scared, even afraid, to let a nurse come to their home for treatments.” The mandate to self-quarantine has not only led to social isolation for these patients, but also in many cases an abrupt halt to participation in critical clinical trials that are advancing potentially life-changing, novel therapies. In a direct response to this, FFF is seeking to partner with digital leaders who have built uniquely deep reach into these patient communities online. “We felt a call to action was needed across a broad range of rare disease spaces to help patients connect and know they are not alone i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.